Renin-Angiotensin-aldosterone system in diabetes and hypertension (Q28308222)

Journal of Clinical Hypertension

Europe PubMed Central

title

Renin-Angiotensin-aldosterone system in diabetes and hypertension (English)

0 references

main subject

arterial hypertension

1 reference

Willa A Hsueh

1

0 references

Kathleen Wyne

series ordinal

2

0 references

language of work or name

English

0 references

publication date

April 2011

0 references

published in

0 references

volume

13

0 references

issue

4

0 references

page(s)

224-37

0 references

cites work

Diabetes and ischemic heart disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Diabetic neuropathies: clinical manifestations and current treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Standards of medical care in diabetes--2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Insufficient control of blood pressure and incident diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Adipokines--targeting a root cause of cardiometabolic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Adipose tissue as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Renin receptor expression in human adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The renin-angiotensin-aldosterone system: a specific target for hypertension management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The underlying mechanisms for development of hypertension in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Minireview: Adiposity, Inflammation, and Atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Endocrine functions of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Local adipose tissue renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Insulin sensitivity: modulation by nutrients and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Mechanisms of disease:Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Prediabetes: the importance of early identification and intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Nonalcoholic fatty liver disease: emerging mechanisms and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Prevalence of fatty liver in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Adiposity of the heart, revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Influence of salt intake on renin-angiotensin and natriuretic peptide system genes in human adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The renin angiotensin system as a therapeutic target to prevent diabetes and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Obesity, essential hypertension and renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Insights into the biology of diabetic vascular disease: what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effect of nateglinide on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Role of the renin-angiotensin- aldosterone system in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Weight loss and the renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Activation of a local renin angiotensin system in podocytes by glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effect of telmisartan on renal outcomes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the Renin-Angiotensin System Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Renal and retinal effects of enalapril and losartan in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Adiponectin suppresses pathological microvessel formation in retina through modulation of tumor necrosis factor-alpha expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Tissue renin-angiotensin system in myocardial hypertrophy and failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Role of angiotensin II in the evolution of diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00449.X